ADAM23 is a member of the brain macrophage-derived chemokine family. Structural homology of ADAM proteins suggests their function as integrin receptors. Previous studies have linked ADAM23 as a dominant contributor to brain development and cancer metastasis. The present studies now show that ADAM23 expression on DCs partially governs antigen-presentation capacities to responder CD4+ T cells. With the use of RNAi approaches, knockdown of ADAM23 in murine BMDCs resulted in impaired T cell activation, proliferation, and cytokine production. Knockdown did not alter the maturation profile of DCs (i.e., costimulatory molecule expression or production of proinflammatory cytokines) but markedly impaired cognate T cell responses. There was a significant decrease in antigen-specific clonal expansion coupled with a global decrease in Th cytokine production. Impaired early activation and proliferation did not alter/skew the balance of Th polarization but significantly depressed total levels of IL-2, IFN-γ, IL-4, and IL-17 cytokine production in CD4+ T cells primed by ADAM23 knockdown versus control DCs. Finally, neutralizing antibodies targeting the α(V)β(3) integrin receptors resulted in similar phenotypes of impaired CD4+ T cell responses. Taken together, these studies show a novel role of ADAM23 in governing DC antigen presentation to cognate CD4+ T cells.
|Original language||English (US)|
|Number of pages||10|
|Journal||Journal of Leukocyte Biology|
|State||Published - Nov 2016|
Bibliographical noteFunding Information:
This work was funded, in part, by the U.S. National Institutes of Health (Grant #1SC2GM103741), Department of Defense (Grant #W911NF-14-1-0123), and National Science FoundationNSF(Grant #1428768). The authors thank Dr. Franklin Ampy for assistance in statistical analyses and Dr. Winston Anderson for revisions and edits of the manuscript.
© Society for Leukocyte Biology.
- Antigen presentation